- Home
- CENN vs PMN Comparison
CENN vs PMN Comparison
Compare CENN & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CENN
- PMN
- Stock Information
- Founded
- CENN 2013
- PMN 2004
- Country
- CENN United States
- PMN Canada
- Employees
- CENN N/A
- PMN N/A
- Industry
- CENN Auto Manufacturing
- PMN Pharmaceuticals and Biotechnology
- Sector
- CENN Consumer Discretionary
- PMN Health Care
- Exchange
- CENN Nasdaq
- PMN Nasdaq
- Market Cap
- CENN 28.3M
- PMN 23.9M
- IPO Year
- CENN N/A
- PMN N/A
- Fundamental
- Price
- CENN $0.83
- PMN $0.71
- Analyst Decision
- CENN
- PMN Strong Buy
- Analyst Count
- CENN 0
- PMN 1
- Target Price
- CENN N/A
- PMN $6.00
- AVG Volume (30 Days)
- CENN 142.4K
- PMN 26.3K
- Earning Date
- CENN 05-11-2025
- PMN 05-13-2025
- Dividend Yield
- CENN N/A
- PMN N/A
- EPS Growth
- CENN N/A
- PMN N/A
- EPS
- CENN N/A
- PMN 0.11
- Revenue
- CENN $31,297,393.00
- PMN N/A
- Revenue This Year
- CENN N/A
- PMN N/A
- Revenue Next Year
- CENN N/A
- PMN N/A
- P/E Ratio
- CENN N/A
- PMN $6.44
- Revenue Growth
- CENN 142.48
- PMN N/A
- 52 Week Low
- CENN $0.64
- PMN $0.62
- 52 Week High
- CENN $2.30
- PMN $2.61
- Technical
- Relative Strength Index (RSI)
- CENN 40.85
- PMN 45.42
- Support Level
- CENN $0.86
- PMN $0.68
- Resistance Level
- CENN $0.98
- PMN $0.76
- Average True Range (ATR)
- CENN 0.07
- PMN 0.06
- MACD
- CENN -0.01
- PMN 0.01
- Stochastic Oscillator
- CENN 4.53
- PMN 50.56
About CENN Cenntro Electric Group Limited
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles. Its vehicles include Metro, Logistar 400, Logistar 200, Neibor 200, and ORV. The company's geographical segments include Europe, America, and Asia.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.